Home > Analytics > AARTI PHARMALABS

AARTI PHARMALABS
Intrinsic Value | Fundamental Analysis

BOM : 543748     NSE : AARTIPHARM    
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive]
Debt : Low
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Mild Upward
Pledged Shares : NA
Nov 19,2024
Price(EOD): ₹ 634.55
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Pharmaceuticals & Drugs
MCap: ₹ 5,749.02 Cr
Value of ₹ 1 Lac invested in AARTI PHARMALABS
on Jan 30,2023 (price: ₹ 377.15)

₹ 1 L

₹ 1.68 L

1W : -3% 1M : 4% 1Y : 63.3%
COMMUNITY POLL
for AARTI PHARMALABS
Please provide your vote to see the results
Industry Peers & Returns1W1M1Y
AARTI PHARMALABS -3% 4% 63.3%
SUN PHARMACEUTICAL INDUSTRIES -1.4% -7.1% 48%
CIPLA -3.5% -5.2% 18%
DR REDDYS LABORATORIES -3.9% -10.1% 10.1%
ZYDUS LIFESCIENCES -0.3% -7.3% 52.2%
DIVIS LABORATORIES 1.5% -2.1% 63%
MANKIND PHARMA -2.3% -3% 39.6%
TORRENT PHARMACEUTICALS -1.8% -10.2% 51.3%
LUPIN -2.4% -6.4% 73.9%

FUNDAMENTAL ANALYSIS OF AARTI PHARMALABS

 
Fundamentals Score
[ Q(TTM): Sep2024, Y: Mar2024
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]


VALUATION OF AARTI PHARMALABS

 
Valuation Score
[As on : Nov 19,2024 ]

Ratio Consolidated
P/E
P/B
P/S
25.21
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 228.09 Cr
[Latest Qtr - Sep2024 - Consolidated Results ]

3.27
P/B Calculated based on Book Value of Rs 1,756.81 Cr
[Latest Year - Mar2024 - Consolidated Results ]

2.92
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 1,967.98 Cr
[Latest Qtr - Sep2024 - Consolidated Results ]

Financial Ratios →

Insights 💡 There are potential 10% undervalued companies ! Discover More →

FAIR VALUE OF AARTI PHARMALABS

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
302%
328%
131%

Insights 💡 You can learn about various Valuation techniques to calculate Intrinsic Value
with our bestselling video course Value Investing - The Ultimate Guide
Take Me There →

SHARE PRICE MOMENTUM OF AARTI PHARMALABS



AARTI PHARMALABS vs SENSEX


Insights 💡 You can learn about Basics of Stock Marketing Investing
with our bestselling video course Stock Marketing Investing Simplified
Take Me There →

DEBT OF AARTI PHARMALABS

Year Debt/Equity ratio
Standalone Consolidated
2024
2023
2022
Avg_3yrs
0.15
0.14
0.26
0.18
0.15
0.14
0.25
0.18
[Last Annual Data : Mar2024]
Financial Ratios →

PLEDGED PROMOTER SHARES OF AARTI PHARMALABS

Pledged Promoter Shares
NA

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad
Shareholding Pattern →

QTRLY RESULTS OF AARTI PHARMALABS

Consolidated Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
-17.55%
-2.89%
-2.59%
-1.5%
4.14%
6.46%
7.2%
5.44%
QtrlyTrend
0
Latest Qtr: Sep2024
Quarterly Result Analysis →


AARTI PHARMALABS related INDICES

BSE Indices1W1M1Y
S&P BSE ALLCAP -0.3% -3.5% 35.8%
S&P BSE HEALTHCARE -2.5% -4% 46.8%
S&P BSE MIDSMALLCAP -2.9% -7% 35.6%
S&P BSE SMALL CAP -3.3% -7.2% 35.2%
No NSE index found

You may also like the below Video Courses


FAQ about AARTI PHARMALABS


Is AARTI PHARMALABS good for long term investment?

As on Nov 19,2024, the Fundamentals of AARTI PHARMALABS look Poor and hence it may not be good for long term investment ! See Financial Performance of AARTI PHARMALABS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is AARTI PHARMALABS UnderValued or OverValued?

As on Nov 19,2024, AARTI PHARMALABS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of AARTI PHARMALABS ?

As on Nov 19,2024, the Intrinsic Value of AARTI PHARMALABS is Rs. 158.04 estimated based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 158.04
Fair Value [Median EV / Sales Model] : Rs. 148.38
Fair Value [Median Price / Sales Model] : Rs. 274.60
Estimated Median Fair Value of AARTI PHARMALABS : Rs. 158.04

The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.

Is AARTI PHARMALABS trading at a Premium or Discount?

As on Nov 19,2024, AARTI PHARMALABS is trading at a Premium of 302% based on the estimates of Median Intrinsic Value!